SG Americas Securities LLC Invests $33,000 in Kodiak Sciences Inc. (NASDAQ:KOD)

SG Americas Securities LLC bought a new stake in shares of Kodiak Sciences Inc. (NASDAQ:KOD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,813 shares of the company’s stock, valued at approximately $33,000.

Other large investors have also recently made changes to their positions in the company. Sanctuary Advisors LLC purchased a new position in shares of Kodiak Sciences in the 2nd quarter valued at about $36,000. Squarepoint Ops LLC acquired a new stake in Kodiak Sciences in the second quarter valued at approximately $127,000. Marshall Wace LLP grew its holdings in Kodiak Sciences by 41.6% in the second quarter. Marshall Wace LLP now owns 166,425 shares of the company’s stock valued at $391,000 after purchasing an additional 48,930 shares during the period. Sei Investments Co. increased its position in shares of Kodiak Sciences by 27.1% in the second quarter. Sei Investments Co. now owns 143,841 shares of the company’s stock valued at $338,000 after buying an additional 30,683 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Kodiak Sciences by 21.9% during the 2nd quarter. Renaissance Technologies LLC now owns 708,800 shares of the company’s stock worth $1,666,000 after buying an additional 127,400 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “neutral” rating and issued a $3.00 price target on shares of Kodiak Sciences in a research note on Tuesday, September 24th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Kodiak Sciences has an average rating of “Hold” and an average target price of $5.00.

Kodiak Sciences Price Performance

NASDAQ KOD opened at $3.93 on Wednesday. The stock’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $2.93. The company has a market cap of $206.78 million, a PE ratio of -1.05 and a beta of 2.34. Kodiak Sciences Inc. has a 1-year low of $1.38 and a 1-year high of $7.77.

Kodiak Sciences (NASDAQ:KOD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.01. On average, equities research analysts anticipate that Kodiak Sciences Inc. will post -3.52 EPS for the current fiscal year.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.